CO5640151A2 - Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer - Google Patents
Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancerInfo
- Publication number
- CO5640151A2 CO5640151A2 CO06008204A CO06008204A CO5640151A2 CO 5640151 A2 CO5640151 A2 CO 5640151A2 CO 06008204 A CO06008204 A CO 06008204A CO 06008204 A CO06008204 A CO 06008204A CO 5640151 A2 CO5640151 A2 CO 5640151A2
- Authority
- CO
- Colombia
- Prior art keywords
- carbon atoms
- combination
- egfr kinase
- inhibitor
- kinase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Una combinación caracterizada porque es de un agente citotóxico y un inhibidor de cinasa EGFR.2.- La combinación de conformidad con la reivindicación 1, caracterizada porque el agente citotóxico se selecciona del grupo que consiste de capecitabina, paclitaxel, 5-FU, FOLFIRI, FOLFOX4, y cisplatina.3.- La combinación de conformidad con la reivindicación 1 ó 2, caracterizada porque el inhibidor de cinasa EGFR inhibe irreversiblemente la cinasa EGFR.4.- La combinación de conformidad con la reivindicación 1, caracterizada porque el inhibidor de cinasa EGFR es un compuesto de la fórmula 1, que tiene la estructura: en donde: X es cicloalquilo de 3 a 7 átomos de carbono, los cuales pueden estar substituidos opcionalmente con uno o más grupos alquilo de 1 a 6 átomos de carbono; o es un anillo de piridinilo, pirimidinilo, o fenilo; en donde el anillo de piridinilo, pirimidinilo, o fenilo puede estar opcionalmente mono-di, o tri-substituido con un substituyente seleccionado del grupo que consiste de halógeno, alquilo de 1-6 átomos de carbono, alquenilo de 2-6 átomos de carbono, alquinilo de 2-6 átomos de carbono, azido, hidroxialquilo de 1-6 átomos de carbono, halometilo, alcoximetilo de 2-7 átomos de carbono, alcanoiloximetilo de 2-7 átomos de carbono, alcoxi de 1-6 átomos de carbono, alquiltio de 1-6 átomos de carbono, hidroxi, trifluorometilo, ciano, nitro, carboxi, carboalcoxi de 2-7 átomos de carbono, carboalquilo de 2-7 átomos de carbono, fenoxi, fenilo, tiofenoxi, benzoilo, bencilo, amino, alquilamino de 1-6 átomos de carbono, dialquilamino de 2 a 12 átomos de carbono, fenilamino, bencilamino, alcanoilamino de 1-6 átomos de carbono, alquenoilamino de 3-8 átomos de carbono, alquinoilamino de 3-8 átomos de carbono, y benzoilamino; n es 0-1; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49213203P | 2003-08-01 | 2003-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640151A2 true CO5640151A2 (es) | 2006-05-31 |
Family
ID=34215843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06008204A CO5640151A2 (es) | 2003-08-01 | 2006-01-30 | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050026933A1 (es) |
| EP (1) | EP1648516A2 (es) |
| JP (1) | JP2007501238A (es) |
| KR (1) | KR20060054412A (es) |
| CN (1) | CN1832757A (es) |
| AR (1) | AR045179A1 (es) |
| AU (1) | AU2004266572A1 (es) |
| BR (1) | BRPI0413255A (es) |
| CA (1) | CA2533126A1 (es) |
| CO (1) | CO5640151A2 (es) |
| CR (1) | CR8181A (es) |
| EC (1) | ECSP066341A (es) |
| IL (1) | IL173081A0 (es) |
| MX (1) | MXPA06001110A (es) |
| NO (1) | NO20060398L (es) |
| RU (1) | RU2006106267A (es) |
| TW (1) | TW200515910A (es) |
| WO (1) | WO2005018677A2 (es) |
| ZA (1) | ZA200600915B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009473A (es) * | 2002-03-29 | 2005-02-03 | Exxonmobil Chem Patents Inc | Oligomerizacion de olefinas. |
| MXPA04009472A (es) * | 2002-03-29 | 2005-02-03 | Exxonmobil Chem Patents Inc | Preparacion de hidrocarburos alquilaromaticos y alquilaril sulfonatos. |
| KR101289774B1 (ko) | 2004-03-31 | 2013-08-07 | 다나-파버 캔서 인스티튜트 인크. | 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법 |
| RU2006146612A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
| RU2006146623A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение оксалиплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
| PL1848414T3 (pl) | 2005-02-03 | 2011-10-31 | Wyeth Llc | Sposób leczenia nowotworu opornego na gefitinib |
| EP2594631A1 (en) | 2005-04-05 | 2013-05-22 | Cellpoint Diagnostics | Devices and method for detecting circulating tumor cells and other particles |
| MX2007012662A (es) * | 2005-04-14 | 2008-04-04 | Wyeth Corp | Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib. |
| RU2447889C2 (ru) * | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
| EP1906977B1 (en) * | 2005-07-21 | 2012-02-22 | Nuvo Research AG | Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
| PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| WO2007139930A2 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007354301A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with PARP inhibitors |
| WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| JP2010503696A (ja) * | 2006-09-13 | 2010-02-04 | ヌベロ， インコーポレイテッド | 癌を処置するための方法 |
| DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP2217227B1 (en) * | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| AU2008321382A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| RU2010128107A (ru) * | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
| EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| CN102202667A (zh) | 2008-08-04 | 2011-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| MY156789A (en) * | 2008-09-05 | 2016-03-31 | Celgene Avilomics Res Inc | Algorithm for designing irreversible inhibitors |
| MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
| SG179172A1 (en) | 2009-09-16 | 2012-04-27 | Avila Therapeutics Inc | Protein kinase conjugates and inhibitors |
| WO2011056741A2 (en) | 2009-11-09 | 2011-05-12 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
| ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
| EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220229072A1 (en) | 2019-06-04 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| AR037438A1 (es) * | 2001-11-27 | 2004-11-10 | Wyeth Corp | 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
-
2004
- 2004-07-28 AU AU2004266572A patent/AU2004266572A1/en not_active Abandoned
- 2004-07-28 US US10/900,655 patent/US20050026933A1/en not_active Abandoned
- 2004-07-28 EP EP04801904A patent/EP1648516A2/en not_active Withdrawn
- 2004-07-28 CA CA002533126A patent/CA2533126A1/en not_active Abandoned
- 2004-07-28 JP JP2006522619A patent/JP2007501238A/ja active Pending
- 2004-07-28 RU RU2006106267/15A patent/RU2006106267A/ru not_active Application Discontinuation
- 2004-07-28 CN CNA2004800217643A patent/CN1832757A/zh active Pending
- 2004-07-28 BR BRPI0413255-6A patent/BRPI0413255A/pt not_active Application Discontinuation
- 2004-07-28 WO PCT/US2004/024478 patent/WO2005018677A2/en active Application Filing
- 2004-07-28 KR KR1020067002252A patent/KR20060054412A/ko not_active Application Discontinuation
- 2004-07-28 MX MXPA06001110A patent/MXPA06001110A/es not_active Application Discontinuation
- 2004-07-29 TW TW093122704A patent/TW200515910A/zh unknown
- 2004-07-30 AR ARP040102724A patent/AR045179A1/es unknown
-
2006
- 2006-01-10 IL IL173081A patent/IL173081A0/en unknown
- 2006-01-11 CR CR8181A patent/CR8181A/es unknown
- 2006-01-25 NO NO20060398A patent/NO20060398L/no not_active Application Discontinuation
- 2006-01-30 CO CO06008204A patent/CO5640151A2/es not_active Application Discontinuation
- 2006-01-31 ZA ZA200600915A patent/ZA200600915B/en unknown
- 2006-02-01 EC EC2006006341A patent/ECSP066341A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0413255A (pt) | 2006-10-03 |
| CA2533126A1 (en) | 2005-03-03 |
| IL173081A0 (en) | 2006-06-11 |
| TW200515910A (en) | 2005-05-16 |
| CN1832757A (zh) | 2006-09-13 |
| RU2006106267A (ru) | 2006-07-27 |
| JP2007501238A (ja) | 2007-01-25 |
| ECSP066341A (es) | 2006-08-30 |
| AU2004266572A1 (en) | 2005-03-03 |
| WO2005018677A3 (en) | 2006-05-26 |
| AR045179A1 (es) | 2005-10-19 |
| EP1648516A2 (en) | 2006-04-26 |
| WO2005018677A2 (en) | 2005-03-03 |
| MXPA06001110A (es) | 2006-04-11 |
| US20050026933A1 (en) | 2005-02-03 |
| KR20060054412A (ko) | 2006-05-22 |
| CR8181A (es) | 2006-07-14 |
| NO20060398L (no) | 2006-02-28 |
| ZA200600915B (en) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640151A2 (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| CL2020002405A1 (es) | Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394) | |
| EA036112B1 (ru) | 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2 | |
| EP4234030A3 (en) | Pd-1/pd-l1 inhibitors | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
| JOP20200209A1 (ar) | مثبطات cd73 | |
| CO6270257A2 (es) | Derivados de piridazinona | |
| AR053357A1 (es) | Uso de un inhibidor de quinasa del receptor del factor de crecimiento epidermico (efgr) en pacientes resistentes a gefitinib | |
| ECSP088752A (es) | Formulaciones para administración parenteral de compuestos y sus usos | |
| MX2009013625A (es) | Compuestos de di (arilamino) arilo. | |
| TW200612950A (en) | Quinazolinedione derivatives as PARP inhibitors | |
| ECSP088218A (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
| PA8537501A1 (es) | Naftostirilos | |
| TW200608977A (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| ME00936B (me) | Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa | |
| UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
| CO5580828A2 (es) | 3-cianoquinolinas como inhibidores de quinasa egf-r y her2 | |
| CL2003002731A1 (es) | Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe | |
| BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
| UY29685A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. | |
| MX2022013619A (es) | Compuestos de 2,4-dioxopirimidina que inhiben cd73. | |
| AR050598A2 (es) | Composicion funguicida sinergica, procedimiento para combatir hongos nocivos y uso de los compuestos que integran dicha composicion para la preparacion de dichas mezclas sinergicas | |
| AR059320A1 (es) | Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico | |
| EP4053122A4 (en) | COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2 ASSOCIATED DISEASE COMPRISING THEM AS AN ACTIVE INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |